The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost its position in ...

The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which incl ...

Sanofi has not had the success it was hoping for with its oral BTK inhibitors, acquired as part of its $3.7 billion buyout of Principia Biopharma, but can now point to a win for rilzabrutinib in ...

Rilzabrutinib is an investigational, oral, reversible BTK inhibitor developed using Sanofi's proprietary TAILORED COVALENCY platform. This technology enables selective inhibition of BTK while ...

Sanofi is to buy Principia Biopharma for up ... Another of Principia’s BTK inhibitors, rilzabrutinib, is being tested in phase 3 for patients with moderate to severe pemphigus, a rare and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

To help address the impact of COPD on patients and communities, global healthcare companies Sanofi and Regeneron are working together to study the ripple effects of COPD and to help create a ...

The B-cell inhibitor market is undergoing significant transformation, driven by a deepening understanding of B-cell biology and its role in a wide range of immune-mediated and oncological diseases ...